trial

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

NCTId NCT04567524
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 34 (actual)
Sponsored by Lyndra Inc.
Primary completion 2020-12-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-08-13
Primary completion
2020-12-22
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
LYN-005

Sponsors

Lyndra Inc.Lead Sponsor
Worldwide Clinical TrialsCollaborator

Investigators

1
Richard Scranton, MD, MPHPrincipal Investigator

Sites

5 total
Long Beach, United StatesAtlanta, United StatesMarlton, United StatesAustin, United StatesRichardson, United States

Linked catalysts

1
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone E — primary completion2020-12-22

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE2
Primary Completion Date
2020-12-22
Status
COMPLETED
relationships
The graph out of here
drug
LYN-005
drug
lead_sponsor
Lyndra Inc.
company
collaborator
Worldwide Clinical Trials
company
indication
Schizophrenia Schizoaffective
indication
Psychotic Disorders
indication
investigator
Richard Scranton, MD, MPH
person